About Us

415 Capital is a specialist venture capital firm dedicated to investing in breakthrough and life-saving medical innovation. For over 30 years, our team has empowered exceptional entrepreneurs through the provision of capital, expertise, and market access.

We exclusively invest in large unmet patient needs in chronic diseases, with an emphasis on cardio & neurovascular disorders, the worldwide leading causes of death and the largest cost driver in the global healthcare systems. Our mission is to improve patient outcomes and quality of life at lower long-term healthcare costs.

Investment Strategy

Sector: Medical Technologies
Stage: Clinical through Commercial
Europe, Israel & North America
€5-15 Million per Company

Sectors we invest in:

  • Structural Heart Disease
  • Heart Failure
  • Aortic & Peripheral Vascular Disease
  • Neurovascular Disease / Stroke
  • Hypertension
  • Electrophysiology
  • Neuromodulation for Chronic Diseases (e.g. Cardiovascular, Sleep Apnea)
  • Medical Imaging
  • Medical Robotics
  • Patient Monitoring

Sectors we do not invest in:

  • Biotech/Pharma
  • Healthcare Services
  • Wellness Products
Submit a business plan

Value Creation

Through close collaborations with leading physicians and healthcare providers, we support entrepreneurs from R&D stage through clinical trial execution and commercialization.

Besides support with clinical, regulatory and reimbursement strategies, we leverage existing commercial partnerships to provide our portfolio companies with access to a €2bn commercial channel in Europe (Uniphar PLC & CoRRect Medical GmbH).
„Creativity is thinking up new things. Innovation is doing new things.“
Theodore Levitt
„The best way to predict the future is to create it.“
Alan Kay

Our History:
Breakthrough Milestones

Since the 1990s our team has pioneered major advancements in cardiovascular and neurovascular care through both investments and technology commercialization, including drug-eluting stents, transcatheter heart valve replacement and repair (aortic, mitral and tricuspid), cerebral embolic protection and renal denervation to treat uncontrolled hypertension.

1990s

Pre-Mounted Coronary Stents

Introduced to market by our team
(AVE acquired by Medtronic for $3.7bn in 1998)

Minimally Invasive Abdominal Aortic Aneurysm Repair

Funded and introduced to market by our team
(IPO on NASDAQ in 2000)

2000s

Transcatheter Aortic Valve Replacement

Funded and introduced to market by our team
(CoreValve acquired by Medtronic for $850m in 2009)

Ultrasound Renal Denervation

Funded and introduced to market by our team
(ReCor Medical acquired by Otsuka for $350m in 2018)

2010s

Transcatheter Mitral Valve Replacement

Funded and introduced to market by our team
(CardiAQ acquired by Edwards LIfesciences for $350 in 2015)

Cerebral Embolic Protection for Stroke Prevention

Funded and introduced to market by our team
(Claret Medical acquired by Boston Scientific for $270m in 2018)

2020s

Low-Profile pVAD for High-Risk PCI & Cardiogenic Shock Patients

Funded and supported by our team since 2020

Next-Generation Bioresorbable Scaffolds for Peripheral Vascular Disease

Funded and supported by our team since 2020

Minimally Invasive Solution for Tricuspid Valve Replacement

Funded and supported by our team since 2022